Market Overview

Theravance Confirms Favorable Ruling from FDA Panel on VIBATIV

Related THRX
Barron's Recap: Ready To Wear?
UPDATE: Bank Of America Downgrades Theravance As Pricing Headwinds Continue

Theravance Inc. (NASDAQ: THRX) today announced a favorable outcome of the Anti-Infective Drugs Advisory Committee (AIDAC) of the U.S. FDA meeting on VIBATIV(R) (telavancin) for the treatment of nosocomial pneumonia (NP) due to susceptible isolates of Gram-positive microorganisms.

Posted-In: News FDA

 

Related Articles (THRX)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters